Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05304481 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 2
Started2022-05-14
View on ClinicalTrials.gov ↗
This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment. Among all the eligible patients, ratio of 7:2:1 for Stage I:II:IIIa of the HCC will be the enrolled strategy of the study to reflect the results of the previous study (Lee, Lee et al. 2015).

Amendment history 2 changes detected by DataLookout

2026-09-02
Primary completion pushed: 2026-12-31 → 2027-12-31
2026-09-02
Completion pushed: 2027-06-30 → 2028-10-30
Trial Details
NCT Number NCT05304481
Lead Sponsor Lukas Biomedical Inc.
Collaborators: Virginia Contract Research Organization Co., Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 95 participants
Start Date 2022-05-14
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-01